Stephens Inc. AR Has $151,000 Stake in Intrexon Corp (XON)

Stephens Inc. AR trimmed its position in Intrexon Corp (NYSE:XON) by 76.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 23,072 shares of the biotechnology company’s stock after selling 76,208 shares during the quarter. Stephens Inc. AR’s holdings in Intrexon were worth $151,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in XON. Cambridge Investment Research Advisors Inc. raised its stake in Intrexon by 4.2% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 45,823 shares of the biotechnology company’s stock worth $300,000 after acquiring an additional 1,835 shares in the last quarter. PNC Financial Services Group Inc. raised its stake in Intrexon by 1.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 161,385 shares of the biotechnology company’s stock worth $1,055,000 after acquiring an additional 2,882 shares in the last quarter. Quantamental Technologies LLC acquired a new stake in Intrexon during the 4th quarter worth $28,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its stake in Intrexon by 64.5% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 14,292 shares of the biotechnology company’s stock worth $99,000 after acquiring an additional 5,604 shares in the last quarter. Finally, John G Ullman & Associates Inc. raised its stake in Intrexon by 38.7% during the 4th quarter. John G Ullman & Associates Inc. now owns 20,800 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 5,800 shares in the last quarter. Institutional investors and hedge funds own 84.92% of the company’s stock.

NYSE XON traded down $0.32 during trading on Friday, reaching $5.31. The company’s stock had a trading volume of 35,007 shares, compared to its average volume of 2,134,535. Intrexon Corp has a twelve month low of $4.05 and a twelve month high of $20.16.

XON has been the topic of several research analyst reports. JMP Securities reiterated a “buy” rating and set a $43.00 price target on shares of Intrexon in a research note on Wednesday, March 6th. Zacks Investment Research upgraded shares of Intrexon from a “hold” rating to a “strong-buy” rating and set a $8.75 price target on the stock in a research note on Saturday, January 12th. Finally, Northland Securities lowered shares of Intrexon from an “outperform” rating to a “market perform” rating in a research note on Friday, March 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $34.00.

In other Intrexon news, SVP Joel D. Liffman sold 3,725 shares of Intrexon stock in a transaction on Friday, January 4th. The shares were sold at an average price of $7.03, for a total value of $26,186.75. Following the transaction, the senior vice president now directly owns 89,266 shares in the company, valued at $627,539.98. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Nir Nimrodi sold 4,058 shares of Intrexon stock in a transaction on Thursday, January 3rd. The shares were sold at an average price of $7.07, for a total transaction of $28,690.06. Following the completion of the transaction, the insider now owns 9,766 shares in the company, valued at $69,045.62. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 296,797 shares of company stock worth $1,403,911. 48.20% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece was reported by WKRB News and is the sole property of of WKRB News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.wkrb13.com/2019/03/15/stephens-inc-ar-has-151000-stake-in-intrexon-corp-xon.html.

About Intrexon

Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.

See Also: Hedge Funds

Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corp (NYSE:XON).

Institutional Ownership by Quarter for Intrexon (NYSE:XON)

Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.